Voyager Therapeutics Crecimiento futuro

Future controles de criterios 0/6

Se prevé que los ingresos y los beneficios de Voyager Therapeutics disminuyan a un ritmo anual de 40.4% y 40.3% respectivamente. Se espera que el BPA disminuya en un 40.2% al año. Se prevé que la rentabilidad financiera sea de -27.3% en 3 años.

Información clave

-40.3%

Tasa de crecimiento de los beneficios

-40.2%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	31.0%
Tasa de crecimiento de los ingresos	-40.4%
Rentabilidad financiera futura	-27.3%
Cobertura de analistas	Good
Última actualización	30 Apr 2024

Actualizaciones recientes sobre el crecimiento futuro

No hay actualizaciones

Recent updates

Previsiones de crecimiento de beneficios e ingresos

DB:VT6 - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	55	-108	-88	-81	7
12/31/2025	51	-106	-64	-59	10
12/31/2024	39	-98	-66	-61	10
12/31/2023	250	132	75	78	N/A
9/30/2023	158	52	86	89	N/A
6/30/2023	195	96	91	94	N/A
3/31/2023	191	99	74	77	N/A
12/31/2022	41	-46	-15	-13	N/A
9/30/2022	71	-17	9	11	N/A
6/30/2022	31	-60	4	6	N/A
3/31/2022	32	-71	1	2	N/A
12/31/2021	37	-71	-55	-54	N/A
9/30/2021	16	-93	-92	-87	N/A
6/30/2021	132	18	-100	-91	N/A
3/31/2021	160	39	-100	-89	N/A
12/31/2020	171	37	-109	-97	N/A
9/30/2020	197	40	-110	-98	N/A
6/30/2020	100	-61	-103	-95	N/A
3/31/2020	117	-41	-113	-105	N/A
12/31/2019	104	-44	41	49	N/A
9/30/2019	74	-54	43	48	N/A
6/30/2019	55	-59	47	52	N/A
3/31/2019	12	-96	57	61	N/A
12/31/2018	8	-88	-20	-16	N/A
9/30/2018	12	-78	-10	-6	N/A
6/30/2018	11	-81	-8	-5	N/A
3/31/2018	10	-74	-1	2	N/A
12/31/2017	10	-71	-65	-61	N/A
9/30/2017	6	-74	N/A	-60	N/A
6/30/2017	8	-59	N/A	-54	N/A
3/31/2017	11	-50	N/A	-47	N/A
12/31/2016	14	-40	N/A	-42	N/A
9/30/2016	17	-34	N/A	-39	N/A
6/30/2016	18	-32	N/A	-36	N/A
3/31/2016	20	-30	N/A	-33	N/A
12/31/2015	17	-38	N/A	41	N/A
9/30/2015	12	-35	N/A	46	N/A
6/30/2015	7	-32	N/A	50	N/A
3/31/2015	3	-30	N/A	55	N/A
12/31/2014	N/A	-18	N/A	-12	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que los beneficios de VT6 disminuyan en los próximos 3 años (-40.3% al año).

Beneficios vs. Mercado: Se prevé que los beneficios de VT6 disminuyan en los próximos 3 años (-40.3% al año).

Beneficios de alto crecimiento: Se prevé que los beneficios de VT6 disminuyan en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos de VT6 disminuyan en los próximos 3 años (-40.4% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos de VT6 disminuyan en los próximos 3 años (-40.4% al año).

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: VT6 se prevé que no sea rentable en 3 años.

Voyager Therapeutics Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Investor sentiment improves as stock rises 16%

Voyager Therapeutics, Inc., Annual General Meeting, Jun 05, 2024

President recently sold €111k worth of stock

Investor sentiment improves as stock rises 17%

Voyager Therapeutics, Inc. Announces Appointment of Toby Ferguson as Chief Medical Officer, Effective March 25, 2024

Voyager Therapeutics, Inc. Announces Appointment of Toby Ferguson as Chief Medical Officer, Effective March 25, 2024

Full year 2023 earnings released: EPS: US$3.08 (vs US$1.21 loss in FY 2022)

Investor sentiment improves as stock rises 27%

Voyager Therapeutics, Inc. Announces Selection of Gene Therapy Development Candidate for Friedreich's Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment

President recently sold €90k worth of stock

Voyager Therapeutics, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Voyager Therapeutics Reports Robust Preclinical Activity in Tau Silencing Gene Therapy Program for Alzheimer's Disease and Advances Program into Late Research

New major risk - Shareholder dilution

Voyager Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Voyager Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $100 million.

Investor sentiment improves as stock rises 26%

Voyager Therapeutics, Inc. Announces Selection of Development Candidate for SOD1 Amyotrophic Lateral Sclerosis Gene Therapy Program

Third quarter 2023 earnings released: US$0.59 loss per share (vs US$0.46 profit in 3Q 2022)

Voyager Therapeutics, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Chief Financial Officer recently sold €91k worth of stock

Second quarter 2023 earnings released: US$0.51 loss per share (vs US$0.50 loss in 2Q 2022)

Voyager Therapeutics, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Investor sentiment deteriorates as stock falls 16%

Voyager Therapeutics Announces Appointment of Jacquelyn Fahey Sandell as Chief Legal Officer

Investor sentiment improves as stock rises 16%

Investor sentiment improves as stock rises 19%

Voyager Therapeutics, Inc. Appoints George Scangos as Director and as Member of Science and Technology Committee

First quarter 2023 earnings released: EPS: US$3.05 (vs US$0.56 loss in 1Q 2022)

President recently sold €54k worth of stock

Chief Operating Officer recently sold €120k worth of stock

Full year 2022 earnings released: US$1.21 loss per share (vs US$1.89 loss in FY 2021)

Voyager Therapeutics, Inc. Appoints Grace E. Colón, Ph.D., to Its Board of Directors, Effective on January 1, 2023

Third quarter 2022 earnings released: EPS: US$0.46 (vs US$0.67 loss in 3Q 2021)

Voyager Therapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Voyager Therapeutics, Inc Presents Data Characterizing a Novel CNS Receptor and Demonstrating the Low-Dose Potential of TRACER™ Generated Capsid Families

Voyager Therapeutics Appoints Peter Pfreundschuh as CFO, Effective September 19, 2022

Second quarter 2022 earnings released: US$0.50 loss per share (vs US$0.80 loss in 2Q 2021)

Voyager Therapeutics Presents New Data Demonstrating Novel Candidate Therapeutic Antibodies Reduced Tau Pathology in Multiple Preclinical Models

Voyager Therapeutics, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Voyager Therapeutics Appoints Catherine J. Mackey, Ph.D. to Its Board of Directors

Voyager Therapeutics, Inc. Announces Executive Changes

Voyager Therapeutics, Inc. to Present New Preclinical Data on Family of AAV9-Derived Tracer Capsids Demonstrating Cross-Species Central Nervous System (CNS) Transduction

Voyager Therapeutics, Inc. to Present Preclinical Data from Its Vectorized Anti-Her2 Antibody Program and A Novel Aav5-Derived Tracer™ Capsid At the 25Th American Society of Gene and Cell Therapy Annual Meeting

First quarter 2022 earnings released: US$0.56 loss per share (vs US$0.58 loss in 1Q 2021)

Voyager Therapeutics, Inc., Annual General Meeting, Jun 06, 2022

Mark Levin and Steven Paul Requests Voyager Therapeutics Not to Nominate for Re-Election to the Board

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Voyager Therapeutics, Inc. Announces Executive Appointments

Third quarter 2021 earnings released: US$0.67 loss per share (vs US$2.30 profit in 3Q 2020)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Second quarter 2021 earnings released: US$0.80 loss per share (vs US$0.23 loss in 2Q 2020)

Voyager Therapeutics, Inc.(NasdaqGS:VYGR) dropped from Russell 3000E Index

Voyager Therapeutics’ Novel Capsids Demonstrate Robust Delivery Across the Blood Brain Barrier, Widespread CNS Transduction in Non-Human Primates

First quarter 2021 earnings released: US$0.58 loss per share (vs US$0.66 loss in 1Q 2020)

Voyager Therapeutics Receives FDA Clearance of IND Application for Gene Therapy Candidate VY-HTT01 for Treatment of Huntington’s Disease

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS US$0.99 (vs US$1.21 loss in FY 2019)

Revenue misses expectations

The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Voyager Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

New 90-day low: €5.30

Voyager Therapeutics, Inc. to Report Q4, 2020 Results on Feb 25, 2021

Zhang Investor Law Alerts Investors of Deadline in Securities Class Action Lawsuit Against Voyager Therapeutics, Inc

Neurocrine Biosciences, Inc. Enters into Partial Termination of the Collaboration and License Agreement with Voyager Therapeutics, Inc

Pomerantz Law Firm Announces the Filing of Class Action Against Voyager Therapeutics, Inc

Wendy Dixon Decides to Resign from the Board and All Committees of Voyager Therapeutics, Inc

Investor sentiment improved over the past week

New 90-day low: €6.00

Investor sentiment deteriorated over the past week

New 90-day low: €6.45

Market pulls back on stock over the past week

Third quarter 2020 earnings released: EPS US$2.30

New 90-day low: €7.50